Cardlytics Deferred Long Term Liab Over Time
| CDLX Stock | USD 2.43 0.01 0.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cardlytics Performance and Cardlytics Correlation. Cardlytics |
Is Advertising space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardlytics. If investors know Cardlytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardlytics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.57) | Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth (0.15) | Return On Assets |
The market value of Cardlytics is measured differently than its book value, which is the value of Cardlytics that is recorded on the company's balance sheet. Investors also form their own opinion of Cardlytics' value that differs from its market value or its book value, called intrinsic value, which is Cardlytics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardlytics' market value can be influenced by many factors that don't directly affect Cardlytics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardlytics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardlytics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardlytics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Deferred Long Term Liab Analysis
Compare Cardlytics and related stocks such as Criteo Sa, Deluxe, and Emerald Expositions Deferred Long Term Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRTO | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 139 K | 0.0 | 0.0 | 10.8 M | 5.3 M | 5.3 M | 3.1 M | 3.1 M | 3.1 M | 3.5 M | 3.2 M |
| DLX | 46.8 M | 49.8 M | 75.1 M | 82.8 M | 95.8 M | 81.1 M | 85.2 M | 50.5 M | 46.7 M | 14.9 M | 10.6 M | 74.5 M | 45.5 M | 45.5 M | 41 M | 46.7 M |
| EEX | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 140.1 M | 100.2 M | 60 M | 60 M | 1.9 M | 1.5 M | 1.8 M | 1.8 M | 1.6 M | 1.5 M |
| MCHX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 M | 981 K | 167 K | 128 K | 128 K | 128 K | 147.2 K | 280.7 K |
| IAS | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 40.9 M | 36.4 M |
| CMPR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 60.7 M | 51.2 M | 44.5 M | 33.8 M | 27.4 M | 41.1 M | 47.4 M | 47.4 M | 54.5 M | 38.4 M |
| QNST | 49 K | 49 K | 239 K | 0.0 | 0.0 | 8.3 M | 7.3 M | 6.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 6.1 M | 3.8 M |
| IPG | 486.1 M | 440.3 M | 489 M | 514.3 M | 16.6 M | 464.2 M | 480.7 M | 476.6 M | 422.7 M | 425 M | 413.2 M | 329.1 M | 294.1 M | 294.1 M | 264.7 M | 323.2 M |
| ADV | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 491.2 M | 483.2 M | 297.9 M | 297.9 M | 268.1 M | 339.3 M |
| BOC | 327 K | 327 K | 327 K | 327 K | 327 K | 327 K | 327 K | 327 K | 1.4 M | 2.3 M | 690.6 K | 23.3 M | 13.9 M | 13.9 M | 16 M | 16.8 M |
| OMC | 488.1 M | 867.6 M | 0.0 | 832.6 M | 654.7 M | 469.1 M | 480.5 M | 483.6 M | 413.7 M | 408.1 M | 443.5 M | 477.3 M | 475.7 M | 475.7 M | 428.1 M | 413.8 M |
Cardlytics and related stocks such as Criteo Sa, Deluxe, and Emerald Expositions Deferred Long Term Liab description
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.My Equities
My Current Equities and Potential Positions
| Cardlytics | CDLX |
Specialization | Communication Services, Media & Entertainment |
| Location | Georgia; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.31
Additional Tools for Cardlytics Stock Analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.